日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

AI-assisted phage formulation delivered via injectable hydrogels for localized control of implant-associated infections

利用人工智能辅助的噬菌体制剂,通过可注射水凝胶递送,用于局部控制植入物相关感染。

Bayat, Fereshteh; Stark, Martin; Rahmani, Sara; Sun, Cindy; Khani, Arman; Ommi, Yassaman; Tian, Lei; Aguilar Lopez, Fiorelle C; Weitz, Jeffrey I; Didar, Tohid F; Hosseinidoust, Zeinab

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial

阿贝拉西单抗与利伐沙班治疗老年房颤患者:AZALEA-TIMI 71 2b 期试验的预设分析

Al Said, Samer; Patel, Siddharth M; Giugliano, Robert P; Morrow, David A; Goodrich, Erica L; Murphy, Sabina A; Hug, Bruce; Parkar, Sanobar; Chen, Shih-Ann; Goodman, Shaun G; Joung, Boyoung; Kiss, Robert G; Wojakowski, Wojciech; Weitz, Jeffrey I; Bloomfield, Dan; Sabatine, Marc S; Ruff, Christian T

Reduced- Compared with Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis

减量直接口服抗凝剂与标准剂量直接口服抗凝剂在静脉血栓栓塞长期治疗中的比较:系统评价和荟萃分析

Cheung, Carmen Ka Man; Carlin, Stephanie; Scheier, Thomas C; Yi, Qi-Long; Chan, Noel C; Bhagirath, Vinai; Petropoulos, Jo-Anne; Wong, Raymond; Weitz, Jeffrey I; Eikelboom, John W

Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial

阿贝拉西单抗与利伐沙班治疗接受抗血小板治疗的房颤患者:AZALEA-TIMI 71试验的预设分析

Al Said, Samer; Patel, Siddharth M; Giugliano, Robert P; Morrow, David A; Goodrich, Erica L; Murphy, Sabina A; Hug, Bruce; Parkar, Sanobar; Chen, Shih-Ann; Goodman, Shaun G; Joung, Boyoung; Kiss, Robert G; Wojakowski, Wojciech; Weitz, Jeffrey I; Bloomfield, Dan; Sabatine, Marc S; Ruff, Christian T

Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71

长效因子XI抑制剂与围手术期出血:来自AZALEA-TIMI 71研究的分析

Patel, Siddharth M; Giugliano, Robert P; Morrow, David A; Parkar, Sanobar; Shapiro, Hannah; Hug, Bruce; Kuder, Julia F; Goodrich, Erica L; Chen, Shih-Ann; Goodman, Shaun G; Joung, Boyoung; Kiss, Robert G; Wojakowski, Wojciech; Weitz, Jeffrey I; Murphy, Sabina A; Wiviott, Stephen D; Bloomfield, Daniel; Sabatine, Marc S; Ruff, Christian T

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

肾功能对使用阿贝拉西单抗抑制因子XI治疗房颤的安全性影响:AZALEA-TIMI 71随机临床试验的预设分析

Patel, Siddharth M; Giugliano, Robert P; Morrow, David A; Goodrich, Erica L; Murphy, Sabina A; Hug, Bruce; Parkar, Sanobar; Chen, Shih-Ann; Goodman, Shaun G; Joung, Boyoung; Kiss, Robert G; Wojakowski, Wojciech; Weitz, Jeffrey I; Bloomfield, Dan; Sabatine, Marc S; Ruff, Christian T

Biologically Active Implants Prevent Mortality in a Mouse Sepsis Model.

生物活性植入物可预防小鼠脓毒症模型中的死亡。

Stark Martin, Bayat Fereshteh, Rahmani Sara, Thirugnanasampanthar Mathura, Kramer Taylor, Schwarz Elise, Wilson David, Weitz Jeffrey I, Hosseinidoust Zeinab, Didar Tohid F

Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis.

抑制细胞表面 GRP78 和活化的 α2M 相互作用可减轻肾纤维化。

Trink Jackie, Nmecha Ifeanyi Kennedy, Pilely Katrine, Li Renzhong, Yang Zi, Kwiecien Sydney, MacDonald Melissa, Gao Bo, Mamai Mariam A, Lu Chao, Bajwa Urooj F, Uppal Nikhil, Fredenburgh James C, Kakoki Masao, Pizzo Salvatore V, Rullo Anthony F, Lanktree Matthew B, Weitz Jeffrey I, Palarasah Yaseelan, Krepinsky Joan C

XI before X: The Promise of Factor XI Inhibitors

XI先于X:因子XI抑制剂的前景

Weitz, Jeffrey I; Alzayer, Husam

Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial

在接受血液透析的肾功能衰竭患者中使用奥索西单抗进行抗凝治疗:一项随机 II 期试验

Weitz, Jeffrey I; Tankó, László B; Floege, Jürgen; Fox, Keith A A; Bhatt, Deepak L; Thadhani, Ravi; Hung, James; Pap, Ákos F; Kubitza, Dagmar; Winkelmayer, Wolfgang C